Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

European HTA Highlights: IQWiG Focuses On Indications, Benefits; NICE Still Obsessed With Cost Controls

Executive Summary

Germany’s IQWiG is concentrating on product benefits in its reviews, though is still expecting carefully tailored studies from sponsors. But industry’s concern in England continues to focus on NICE’s obsession with saving the NHS money – meaning pharma must make innovation cheaper to succeed.

You may also be interested in...



Oncologists Audition Yervoy And Zelboraf For First-line Roles, With New Combos In Near Sight

Cooperative group plans trial testing Yervoy vs. Zelboraf in first-line metastatic melanoma to help settle the issue of which therapy should come first in BRAF-mutation positive patients. New therapies on the way promise to further complicate decision-making.

Xarelto, Pradaxa Difficult To Separate After Positive NICE Final Guidance

Bayer’s Xarelto has made it into the NHS in England after its NICE recommendation went unchallenged, prompting a head to head battle with Boehringer Ingelheim’s Pradaxa.

Benlysta And Fampyra Fail to Make Headway As IQWiG Tightens Comparator Screw

Germany’s health technology evaluator’s rejection of GSK’s Benlysta and Biogen Idec’s Fampyra could force companies to design separate trials for authorization and HTA assessment.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143367

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel